Serimmune COVID Antibody Epitope Mapping Service
Serimmune has launched a COVID antibody epitope mapping discovery service, which leverages the company's serum epitope repertoire analysis (SERA) technology. The service requires 100 ul of serum or plasma per sample, which Serimmune analyzes for IgG and/or IgM antibodies using its proprietary, 10-billion-member, random, bacterial peptide display library. The service provides a composite score of the antibody epitopes identified in each sample to those observed in cohorts of individuals with mild, moderate, and severe COVID-19 disease. It also provides single amino acid-resolution epitope data across the entire SARS-CoV-2 proteome for each sample and shows how it compares to a large cohort of pre-pandemic controls and SARS-COV-2 positive samples, the company said.